Anzeige
02.06.2023 | Systematic Review
The Efficacy of SARS-CoV-2 Vaccination in the Elderly: A Systemic Review and Meta-analysis
Erschienen in: Journal of General Internal Medicine
Einloggen, um Zugang zu erhaltenAbstract
Background
Given the reduced immune response to vaccines in older populations, this study aimed to evaluate the efficacy of COVID-19 vaccinations and its impact on breakthrough infection, hospital admission, and mortality in the elderly.
Methods
We carried out a systemic review and meta-analysis where MEDLINE, Web of Science, EMBASE, ClinicalTrials.gov, and Cochrane Central Register for Controlled Trials were queried to identify relevant literature. We included randomized controlled trials (RCTs), non-randomized trials, prospective, observational cohort, and case–control studies assessing breakthrough infection, hospital admission, and mortality after coronavirus 2 (SARS-CoV-2) vaccination in the elderly (≥ 60 years old).
Results
Overall, 26 studies were included in this meta-analysis. Compared with the unvaccinated group, the vaccinated group showed a decreased risk of SARS-CoV-2 infection after 28–34 (relative risk [RR] = 0.42, 95% confidence interval [CI] 0.37–0.49) and 35–60 days (RR = 0.49, 95% CI 0.37–0.62). There was a step-wise increase in efficacy with additional doses with the two-dose group experiencing decreased risk of breakthrough infection (RR = 0.37, 95% CI 0.32–0.42), hospital admissions (RR = 0.25, 95% CI 0.14–0.45), disease severity (RR = 0.38, 95% CI 0.20–0.70), and mortality (RR = 0.21, 95% CI 0.14–0.32) compared with those receiving one or no doses. Similarly three-dose and four-dose vaccine groups also showed a decreased risk of breakthrough infection (3-dose: RR = 0.14, 95% CI 0.10–0.20; 4-dose RR = 0.46, 95% CI 0.4–0.53), hospital admissions (3-dose: RR = 0.11, 95% CI 0.07–0.17; 4-dose: RR = 0.42, 95% CI 0.32–0.55), and all-cause mortality (3-dose: RR = 0.10, 95% CI 0.02–0.48; 4-dose: RR = 0.48, 95% CI 0.28–0.84) Subgroup analysis found that protection against mortality for vaccinated vs. unvaccinated groups was similar by age (60–79 years: RR = 0.59; 95% CI, 0.47–0.74; ≥ 80 years: RR = 0.76; 95% CI, 0.59–0.98) and gender (female: RR = 0.66; 95% CI, 0.50–0.87, male: (RR = 0.58; 95% CI, 0.44–0.76), and comorbid cardiovascular disease (CVD) (RR = 0.69; 95% CI, 0.52–0.92) or diabetes (DM) (RR = 0.59; 95% CI, 0.39–0.89.
Conclusions
Our pooled results showed that SARS-CoV-2 vaccines administered to the elderly is effective in preventing prevent breakthrough infection, hospitalization, severity, and death. What’s more, increasing number of vaccine doses is becoming increasingly effective.